This Federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $404,917 to Quench Medical Inc., a for-profit manufacturer of medical goods, to develop and test an inhaled dry powder formulation containing the psychoplastogenic compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treating opioid use disorder (OUD). The goal is to create a targeted inhalation treatment that can efficiently deliver 5-MeO-DMT to the lungs and systemic circulation, addressing the significant unmet need for new treatment strategies for OUD. Quench Medical has extensive experience developing inhaled dry powder therapeutics, including prior federal grants for lung cancer and pulmonary air leak treatments. This project will leverage Quench's proprietary inhalation drug delivery technology to produce a consistent and effective 5-MeO-DMT formulation, with the objective of demonstrating in-vivo efficacy for reducing OUD symptoms. The award period is from June 1, 2024 to May 31, 2025.
Generated 3/18/25, 2:05 AM